The current status of neonatal extracorporeal membrane oxygenation

Abstract

Marked changes have occurred in the practice of neonatal extracorporeal membrane oxygenation (ECMO) since the first survivor in 1975. Coagulation management has been markedly refined, new catheters allow ECMO to be done either in a venoarterial or venovenous (VV) mode, depending on cardiac function in the infant. A new design of the VV catheter will allow this technique to be used in more infants in the future. New therapies for respiratory failure have changed the complexion of the population being treated with ECMO. The 34 to 36 week gestation infant with respiratory distress syndrome and/or pulmonary hypertension rarely needs ECMO therapy due to the effectiveness of surfactant and high frequency oscillation. Present day survival for infants treated with ECMO for many diagnostic categories ranges between 90% to 100%. The effects of new interventions must be evaluated with regard to their effect on morbidity when being considered prior to ECMO. Neuro-developmental outcome is encouraging, but does indicate that ECMO and the near-miss ECMO patients need to be followed closely into school age. The number of patients being treated per ECMO center has dropped significantly over the last 10 years from 18 to 9. This brings forward the question about regional needs for ECMO Centers and how to assure that centers have enough patients to maintain their clinical competencies. The challenge for the future is where to place ECMO as a therapy. Should it remain a rescue therapy? Or should there now be a trial comparing ECMO to conventional therapies, with morbidity and cost of care as the outcome variables?